Matthew Perrone

March 24, 2010 | Daily Report Online

When historians write the book on how President Barack Obama's health care overhaul became law, they'll need to leave space for some unlikely advocates: lobbyists for the drug, insurance and hospital industries.Last summer, executives from those groups visited the White House and pledged to do their part to help pay for the health bill.

By Matthew Perrone

7 minute read

February 28, 2007 | Daily Report Online

By Matthew Perrone

5 minute read

July 01, 2008 | Daily Report Online

All those speculators getting the blame for driving up the price of oil these days-just who are they For part of the answer, look in the mirror.The retirement savings of workers across the country, entrusted to pension fund managers, are being plowed into one of the few investments that has delivered phenomenal returns in recent years.

By MATTHEW PERRONE

5 minute read

September 08, 2008 | Daily Report Online

WASHINGTON AP - As Congress returns from summer recess, lawmakers are expected to continue needling pharmaceutical makers and health insurers with investigations, while holding off on major health care reform until next year.Democrats this year have launched probes of some of the country's largest drugmakers and passed laws curbing marketing tactics used by insurers.

By MATTHEW PERRONE

4 minute read

May 09, 2013 | Daily Report Online

State pharmacy officials on Thursday threw their support behind a proposal giving the Food and Drug Administration authority over large compounding pharmacies, in an effort to head off more outbreaks tied to contaminated medications.

By Matthew Perrone

4 minute read

September 15, 2006 | Law.com

A U.S. District Court judge in Washington, D.C., has opened the door for drug companies to market competing versions of Wellbutrin, an anti-depressant drug made by Biovail. The drug maker requested a temporary restraining order and preliminary injunction against the FDA to prevent it from approving the marketing of generic versions of Wellbutrin. The judge concluded that Biovail did not show how the marketing of a generic version would cause the "irreparable injury" needed to justify a restraining order.

By Matthew Perrone

2 minute read

August 02, 2007 | Law.com

A trade group that includes Google Inc., Microsoft Corp. and other high-tech companies has asked federal regulators to order changes in copyright warnings. Copyright statements that appear at the start of most DVDs, pro sports broadcasts and movies go too far and discourage legal use of the content, the Computer and Communications Industry Association said in a statement Wednesday.

By Matthew Perrone

3 minute read

December 07, 2006 | Law.com

The food industry is urging regulators to allow broader health claims on "functional foods" like energy drinks and power bars, but consumer group critics said this week that the claims are often inflated and misleading. Also this week, the Center for Science in the Public Interest threatened to sue Coca-Cola and Nestle over a new drink, Enviga, that claims on its Web site to burn more calories than it contains and to help drinkers maintain an ideal weight.

By Matthew Perrone

3 minute read

March 27, 2007 | Law.com

A top drug regulator told lawmakers Monday it could be a decade or more before science is available to safely approve generic versions of biotech drugs as easily as traditional drugs. Food and Drug Administration deputy commissioner Janet Woodcock's testimony could benefit companies such as Amgen and Genentech, which have never faced generic competition in the U.S. That lack of competition would change under a recently introduced bill that would task FDA with approving generic versions of biotech medicines.

By Matthew Perrone

4 minute read

February 02, 2010 | Law.com

Boston Scientific said Monday it will pay medical device rival Johnson & Johnson $1.73 billion to settle several seven-year-old patent disputes over drug-coated stents. Boston Scientific will pay Johnson & Johnson's Cordis unit $1 billion this week and $725 million next January. The settlement resolves three patent disputes dating back to 2003, and avoids jury trials that were scheduled to begin later this month.

By Matthew Perrone

3 minute read